The viral illness kills more people in the city than HIV, but antiviral medications may be helping cut its transmission.

Collaboration with South Korean university advocates early antiviral treatment for hepatitis B | Feb. 5, 2025 13:09 ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Honourable Chair, Dr Jerome Walcott, Honourable Ministers, dear colleagues and friends, Good morning, happy New Year, and welcome once again to your WHO headquarters. As you know, for me 2024 ended ...

Harmony Flow CBD Gummies for stress & pain relief. Natural, non-psychoactive & effective. Buy now from the official website!

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Corticosteroid therapy induces clinical, laboratory and histological improvements in 80% of patients with autoimmune hepatitis. Prednisone, alone or at a lower dose in combination with ...

13–16 The focus here will be on a brief history on cccDNA research and its experimental difficulties, and on recent developments and how they may translate into new, curative treatments for chronic ...

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...

With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV ... in 9% to 10% of participants with chronic HBV infection. That is below the 30% ...